Skip to main content

Table 1 Patient characteristics

From: Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy

Age at PCa diagnosis Median (range)
64 (48–78)
Initial T-stage n (%)
 T2a/b 6 (7.7)
 T2c 22 (28.2)
 T3a 18 (23.1)
 T3b 32 (41.0)
Initial N stage n (%)
 N0 62 (79,5)
 N1 16 (20,5)
Surgical margins n (%)
 R0 48 (61,5)
 R1 30 (38,5)
Initial risk group n (%)
 Intermediate 3 (3.9)
 High 29 (37.2)
 Very high 46 (58.8)
Initial PSA (ng/ml) Median (range)
11.4 (2.8–231.0)
First PSA after RP (ng/ml) Median (range)
0.07 (0.0–1.9)
Interval in months from RP to sRT Median (range)
11.16 (3.1–172.6)
PSA nadir after sRT (ng/ml) Median (range)
0.84 (0.0–12.2)
Interval in months from sRT to PSA recurrence Median (range)
22.7 (3.0–136.6)
Biochemical non-response after sRT n (%)
4 (5.1)
PSA level at PSMA-PET imaging (ng/ml) Median (range)
1.9 (0.1–22.1)
Patients with ADT at PSMA-ligand PET imaging n (%)
3 (3.9)
PSA-dt at time of PSMA-PET imaging (months) n (%)
  < 3 (n) 3 (3.9)
 3–6 (n) 32 (41.0)
  > 6–12 (n) 23 (29.5)
  > 12 (n) 16 (20.5)
unknown 4 (5.1)
  1. ADT androgen deprivation therapy, dt doubling time, PCa prostate cancer, PSMA-PET prostate-specific membrane antigen positron emission tomography, PSA prostate-specific antigen, RP radical prostatectomy, sRT salvage radiotherapy